Markus Queisser

Markus Queisser

Company: GlaxoSmithKline

Job title: Scientific Director


Utilizing PROTACs to Degrade Kinases with Increased Selectivity, Improved Efficacy or PK/PD Disconnect Using Multiple Examples 1:30 pm

Highlighting the advantages of using a degrader vs. catalytic site inhibitors and determining high specificity to minimize off-target effects Optimizing the linkers and E3 ligand for maximal binding, optimize residency time and improving the durability of kinase inhibitor therapeutics Discovering and characterizing a highly cooperative FAK-GSK215-VHL ternary complexRead more

day: Day One

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.